Meta-Analysis of the Efficacy and Safety of Uninterrupted NOACs in Patients Undergoing Atrial Fibrillation Catheter Ablation
- Author:
Zi-Nan ZHAO
1
Author Information
- Publication Type:Journal Article
- Keywords: Atrial fibrillation; Catheter ablation; Meta-analysis; Novel oral anticoagulation; Randomized clinical trial
- From: Chinese Pharmaceutical Journal 2019;54(10):819-822
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To systematically assess the efficacy and safety of uninterrupted novel oral anticoagulation (NOAC) in patients undergoing atrial fibrillation catheter ablation. METHODS: Databases including multiple databases were searched electronically for randomized controlled trial (RCT) of NOAC in patients undergoing atrial fibrillation catheter ablation up to October, 2018. Two reviewers independently screened literatures according to the inclusion and exclusion criteria, extracted data, and assessed the methodological quality of the included studies. Then Meta-analysis was performed using Rev Man 5.3 software. RESULTS: A total of 5 RCTs involving 1 843 patients were included. Experimental group including apixaban, rivaroxaban and dabigatran; control group using warfarin. Efficacy outcome including stroke and transient ischemic attack (TIA); safety outcome was major bleeding. RESULTS were as followsthere was no significant difference between experimental group and control group in efficacy outcome; the safety of the experimental group was significantly superior to that of the control group. CONCLUSION: Compared with warfarin, uninterrupted NOACs during percutaneous atrial fibrillation catheter ablation could reduce the risk of major bleeding and would not increase the incident of stroke and TIA.
